Elicio Therapeutics, Inc. (ELTX) AI Stock Analysis

Elicio Therapeutics, Inc. is a Boston-based clinical-stage biotechnology firm focused on creating immunotherapies for cancer treatment. Its lead candidate, ELI-002, is a multivalent lymph node-targeted AMP peptide vaccine in Phase II clinical trials targeting seven driver mutations of KRAS. The company is also developing ELI-007 to target BRAF mutations found in solid tumors and ELI-008 to address hotspot mutations of the tumor suppressor protein p53. With 33 employees, Elicio leverages its proprietary platform and partnerships to advance treatments addressing critical unmet needs in oncology.

Elicio Therapeutics operates as a clinical-stage biotech and recorded $0 in revenue for the trailing twelve months ending June 30, 2026, with an operating margin of 0.0% and an eps_ttm of -$2.16. In prior reported annual periods, revenue fluctuated significantly, moving from $6.6M in FY2013 down to $1.5M in FY2019 before jumping 883.1% to $28.3M in FY2021. Net losses were -$20.0M in FY2018, -$40.7M in FY2019, -$80.1M in FY2020, and -$26.4M in FY2021 as research and development expenses expanded to $48.6M. Operating margin stood at -138.8% in FY2021, while trailing twelve month return on equity reached -774.6%.

As of June 30, 2026, Elicio held $23.5M in cash and short-term investments against total debt of $14.1M, yielding net cash of $9.3M. Total assets stood at $31.3M and shareholders' equity was $7.9M. The company maintains short-term liquidity with a current ratio of 2.77, alongside a debt-to-equity ratio of 1.78. In FY2025, capital expenditures were modest at $16,000, while the five-year share count increased by 542.4%.

At a share price of $1.56, Elicio has a market capitalization of $42.3M and an enterprise value of $39.7M. The stock trades at a price-to-book multiple of 6.2x. In comparison, the median of its US-listed Healthcare peers displays an enterprise value to EBITDA multiple of 12.0x, a price-to-sales multiple of 4.1x, and a forward price-to-earnings ratio of 17.3x. Over the past year, ELTX fell 84.5%, significantly lagging the 16.8% return of the S&P 500, while its five-year loss of 98.2% compares to an 83.0% gain for the benchmark.

Wall Street coverage includes 3 Strong Buy ratings and 1 Hold rating from analysts. The mean price target is $13.67, representing a 776.1% premium over the last closing price of $1.56. For the current fiscal year ending December 31, 2026, analysts estimate an EPS of -$1.89 on $0 of revenue. For the following fiscal year, 4 analysts project an EPS of -$1.69 on $0 in revenue. Over the last four quarters, the company has beaten EPS expectations 1 time, with its next earnings report scheduled for November 12, 2026.

This page is an AI-written research summary of Elicio Therapeutics, Inc. (ELTX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ELTX income statement, ELTX balance sheet, ELTX key metrics, ELTX analyst forecast, ELTX chart. See the ELTX stock overview for the latest quote and news.